Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma

Key Points

• The research aims to characterize cytokine release syndrome (CRS) associated with talquetamab in patients with relapsed/refractory multiple myeloma.
• Analysis of adverse events related to talquetamab therapy.
• Description of clinical implications for managing CRS.
• Review of patient responses and treatment outcomes.
• CRS is a common adverse event during talquetamab treatment.
• Effective management strategies for CRS were identified.
• Implications for improving patient outcomes during therapy were highlighted.